214 related articles for article (PubMed ID: 30798622)
41. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
42. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
[TBL] [Abstract][Full Text] [Related]
43. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease.
Quail MA; Russell RK; Van Limbergen JE; Rogers P; Drummond HE; Wilson DC; Gillett PM
Inflamm Bowel Dis; 2009 May; 15(5):756-9. PubMed ID: 19107785
[TBL] [Abstract][Full Text] [Related]
44. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
[TBL] [Abstract][Full Text] [Related]
45. Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives.
Chaabouni T; Manceau H; Peoc'h K
Ann Biol Clin (Paris); 2016 Aug; 74(4):385-94. PubMed ID: 27492691
[TBL] [Abstract][Full Text] [Related]
46. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.
Kostakis ID; Cholidou KG; Vaiopoulos AG; Vlachos IS; Perrea D; Vaos G
Dig Dis Sci; 2013 Feb; 58(2):309-19. PubMed ID: 22899243
[TBL] [Abstract][Full Text] [Related]
47. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease.
Egea Valenzuela J; Pereñíguez López A; Pérez Fernández V; Alberca de Las Parras F; Carballo Álvarez F
Rev Esp Enferm Dig; 2016 Jul; 108(7):394-400. PubMed ID: 27312194
[TBL] [Abstract][Full Text] [Related]
48. Fecal Calprotectin as a Screening Marker for Inflammatory Bowel Disease.
Sridhar M; Kesavelu D
Indian Pediatr; 2019 Mar; 56(3):249-250. PubMed ID: 30955002
[TBL] [Abstract][Full Text] [Related]
49. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
Konikoff MR; Denson LA
Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
[TBL] [Abstract][Full Text] [Related]
50. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
Burri E; Beglinger C
Swiss Med Wkly; 2012; 142():w13557. PubMed ID: 22481443
[TBL] [Abstract][Full Text] [Related]
51. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
[TBL] [Abstract][Full Text] [Related]
52. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
53. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
54. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
Stragier E; Van Assche G
Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease.
Kittanakom S; Shajib MS; Garvie K; Turner J; Brooks D; Odeh S; Issenman R; Chetty VT; Macri J; Khan WI
Can J Gastroenterol Hepatol; 2017; 2017():1450970. PubMed ID: 28491862
[No Abstract] [Full Text] [Related]
56. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
57. Role of fecal calprotectin in the assessment of intestinal inflammation in children with familial Mediterranean fever.
Gucenmez OA; Kume T; Makay B; Babayigit O; Arslan N; Unsal E
Int J Rheum Dis; 2018 Oct; 21(10):1844-1848. PubMed ID: 30345692
[TBL] [Abstract][Full Text] [Related]
58. Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease.
Liu R; Guo Z; Cao L; Wang Z; Gong J; Li Y; Zhu W
Dis Colon Rectum; 2019 Mar; 62(3):318-326. PubMed ID: 30451756
[TBL] [Abstract][Full Text] [Related]
59. [Role of biological markers in inflammatory bowel disease].
Gisbert JP; González-Lama Y; Maté J
Gastroenterol Hepatol; 2007 Mar; 30(3):117-29. PubMed ID: 17374324
[TBL] [Abstract][Full Text] [Related]
60. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease.
Røseth AG; Aadland E; Grzyb K
Scand J Gastroenterol; 2004 Oct; 39(10):1017-20. PubMed ID: 15513345
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
